815-P: CGM-Derived Model-Based Postprandial Glucose with IcoSema vs. Other Insulin Regimens—A Post Hoc Analysis of COMBINE 1 and 3

by sugaradmin



Introduction and Objective: This post hoc analysis investigated whether IcoSema, a once-weekly (OW) combination therapy of basal insulin icodec and the GLP-1 analog semaglutide currently in development, offers a postprandial glucose (PPG) control benefit vs other insulin-based regimens.Methods: COMBINE 1 and 3, two 52-week, phase 3a trials, investigated IcoSema vs OW basal insulin (icodec; COMBINE 1) or basal-bolus therapy (glargine U100 + aspart; COMBINE 3) in adults with T2D who were inadequately controlled on daily basal insulin. This analysis evaluated CGM data (Dexcom G6) collected during weeks 48-52 of both trials. To determine the effect of IcoSema vs comparators on PPG parameters, an algorithm based on model-derived estimates of meal intake to identify increases in PPG was used (GRID algorithm).Results: Statistically significantly lower increments in PPG peak and 90-minute PPG peak were seen with IcoSema vs OW basal insulin (Table). There were no statistically significant differences in AUC90min with IcoSema vs OW basal insulin. No statistically significant differences were observed in CGM-derived PPG parameters with IcoSema vs basal-bolus therapy.Conclusion: Based on post hoc modelling using CGM data, IcoSema showed statistically significantly better PPG control vs OW basal insulin and similar PPG control vs basal-bolus therapy.

Disclosure

C. De Block: Consultant; Abbott, AstraZeneca, Boehringer-Ingelheim, A. Menarini Diagnostics, Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk. M. Asong: Employee; Novo Nordisk A/S. A. Fu: None. R. Maltesen: Employee; Novo Nordisk A/S. F. Giorgino: Advisory Panel; Abbott. Consultant; Amgen Inc. Advisory Panel; AstraZeneca, Bayer Pharmaceuticals, Inc, Biomea Fusion, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly and Company. Research Support; Eli Lilly and Company. Board Member; European Association for the Study of Diabetes. Consultant; Medtronic. Advisory Panel; Mundipharma, Novo Nordisk, Roche Diabetes Care. Research Support; Roche Diabetes Care. Advisory Panel; Sanofi.

Funding

Novo Nordisk A/S



Source link